Drug Profile
Research programme: metabolic disorders therapy - De Novo Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator De Novo Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in United Kingdom
- 16 May 2006 Preclinical trials in Metabolic disorders in United Kingdom (unspecified route)